Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer

Cancer Research

Volumn 64, Issue 20, 2004, Pages 7622-7628

  Yu, Chunyuan ^a   Zhou, Yifeng ^a   Miao, Xiaoping ^a   Xiong, Ping ^a   Tan, Wen ^a   Lin, Dongxin ^a  

^a CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; LUCIFERASE; MESSENGER RNA;

ALLELE; ARTICLE; CANCER RISK; CARCINOGENESIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; ESOPHAGUS CANCER; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALLELES; BINDING SITES; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HAPLOTYPES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RISK FACTORS; SP1 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 5644232084     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1521     Document Type: Article

References (39)

1. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91:439-42.
2. Chambers AF, Matrissian LM. Changing views of the role of matrix metalloproteinase in metastasis. J Natl Cancer Inst (Bethesda) 1997;89:1260-70.
3. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189:300-8.
4. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
5. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000;10:415-33.
6. Nagase H, Woessner JF Jr. Matrix metalloproteinase. J Biol Chem 1999;274:21491-4.
7. Sternlicht MD, Werb Z. Matrix metalloproteinase. In: Kreis T, Vale R, editors. Guidebook to the extracellular matrix, anchor and adhesion proteins. New York: Oxford University Press; 1999. p. 503-603.
8. Levi E, Fridman R, Miao H-Q, Ma Y-C, Yayon A, Voldavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996;93:7069-74.
9. Samantaray S, Sharma R, Chattopadhyaya TK, Gupta SD, Ralhan R. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2004;130:37-44.
10. Yamashita K, Upadhay S, Mimori K, Mori H, Mori M. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer (Phila.) 2003;97:2412-9.
11. Koyama H, Iwata H, Kuwabara Y, Iwase H, Kobayashi S, Fujii Y. Gelatinolytic activity of matrix of matrix metalloproteinase-2 and -9 in oesophageal carcinoma: a study using in situ zymography. Eur J Cancer 2000;36:2164-70.
12. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1977;17: 6330-8.
13. Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999;274:29130-7.
14. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of SpI in allele-specific transcriptional regulation. J Biol Chem 2000;276:7549-58.
15. Vasku V, Vasku A, Tschoplova S, Izakovicova Holla L, Semradova V, Vacha J. Genotype association of C(-735)T polymorphism in matrix metalloproteinase 2 gene with G(8002)A endothelin 1 gene with plaque psoriasis. Dermatology 2002; 204:262-5.
16. Yu C, Pan K, Xing D, et al. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 2002;62:6430-3.
17. Miao X, Yu C, Tan W, et al. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 2002;63:3987-90.
18. Zhou Y, Yu C, Miao X, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis (Lond) 2003;25:399-404.
19. Song C, Xing D, Tan W, Wei Q, Lin D. Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 2001;61:3272-5.
20. Sobin LH, Wittekind C. UICC TNM classification of malignant tumors, 5th ed. New York: Wiley-Leiss; 1997.
21. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
22. Ott J. Predicting the range of linkage disequilibrium. Proc Natl Acad Sci USA 2000;97:2-3.
23. Drysdale C, McGraw D, Stack C, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000;97:10483-8.
24. Liu JF, Wang QZ, Hou J. Surgical treatment for cancer of the oesophagus and gastric cardia in Hebei, China. Br J Surg 2004;91:90-8.
25. Xing D, Tan W, Lin D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population (Review). Oncol Rep 2003;10:1615-23.
26. Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding transcription factor SpI and functional analysis of the DNA binding domain. Cell 1987;51:1079-90.
27. Turner J, Crossley M. Mammalian Kruppel-like transcription factors: more than just a pretty finger. Trends Biochem Sci 1999;24:236-40.
28. Margana RK, Boggaram V. Functional analysis of surfactant protein B (SP-B) promoter SpI, Sp3, TTF-1, and HNF-3alpha transcription factors are necessary for lung cell-specific activation of SP-B gene transcription. J Biol Chem 1997;272:3083-90.
29. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-51.
30. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
31. Ha HY, Moon HB, Nam MS, et al. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Res 2001;61:984-90.
32. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 2001;61:7825-9.
33. Ghilardi G, Biondi ML, Mangoni J, et al. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 2001;7:2344-6.
34. Hinoda Y, Okayama N, Takano N, et al. Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 gene with colorectal cancer. Int J Cancer 2002;102:526-9.
35. Nishioka Y, Kobayashi K, Sagae S, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res 2000;91:612-5.
36. Kanamori Y, Matsushima M, Minaguchi T, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancer and insertion/deletion polymorphism in its promoter region. Cancer Res 1999;59:4225-7.
37. Ghilardi G, Biondi ML, Caputo M, et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res 2002;8:3820-3.
38. Shima I, Sasaguri Y, Kusukawa J, et al. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma: a clinicopathological study. Cancer (Phila.) 1992;70:2747-53.
39. Ye S, Dhillon S, Turner SJ, et al. Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res 2001;61: 1296-8.